Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China.
- Author:
Kai Xin DU
1
;
Hao Rui SHEN
1
;
Li WANG
1
;
Jin Hua LIANG
1
;
Jia Zhu WU
1
;
Yue LI
1
;
Yi XIA
1
;
Hua YIN
1
;
Jian Yong LI
1
;
Wei XU
1
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Adult; Lymphoma, Mantle-Cell/drug therapy*; Rituximab/therapeutic use*; Bendamustine Hydrochloride/therapeutic use*; Lymphoma, B-Cell/pathology*; Lymphoma, Non-Hodgkin/drug therapy*; Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From: Chinese Journal of Hematology 2023;44(4):333-336
- CountryChina
- Language:Chinese
